Activity | Sub-activity | Type of Activity | Duration | Quantified Results | ||||
Eligible | Non-eligible | Full Duration
(no. of months) |
Starting Date
(month) |
End Date
(month) |
||||
(1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) | |
Activities of fundamental research – NOT THE CASE | ||||||||
Activities of industrial research | ||||||||
Activity 1
Industrial research Case-control study on Nrf2 signature in Alzheimer’s disease (AD) and mild cognitive impairment (MCI) |
1.1 Sub-activity 1.1.
Design of the case-control study |
X | 6 | 1 | 6 | 1 case-control study design
7 preliminary Standard Operating Procedures |
||
1.2 Sub-activity 1.2.
Case-control study on Nrf2 signature in AD and MCI |
X | 34 | 7 | 40 | Biological samples
1 database with demografic, clinical and biological data of AD patients, MCI patients and controls 1 study report |
|||
1.3 Sub-activity 1.3.
Set-up of the study-specific biobank |
X | 37 | 5 | 41 | 1 case-control study-specific biobank
1 biological samples registry |
|||
1.4 Sub-activity 1.4.
Set-up of patients data repository |
X | 37 | 5 | 41 | 1 data repository of the cross-sectional study | |||
1.5 Sub-activity 1.5.
Statistical processing of data and connection of data in redox networks |
X | 10 | 37 | 46 | 1 case-control study report
1 redox network in AD and MCI as compared to controls |
|||
Activity 2
Industrial research Proof-of-principle study on pharmacological modulation of Nrf2 signature in preclinical models of Alzheimer’s disease |
2.1 Sub-activity 2.1.
Design of thepreclinical proof-of-principle study |
X | 5 | 13 | 17 | 1 report on the preclinical study design
6 preliminary Standard Operating Procedures |
||
2.2 Sub-activity 2.2.
Selection of preclinical models relevant for Nrf2 signature in Alzheimer’s disease |
X | 12 | 18 | 29 | 1 selected animal model of disease relevant for Nrf2 signature in AD | |||
2.3 Sub-activity 2.3.
Preclinical proof-of-principle study based on pharmacological activation of Nrf2 in Alzheimer’s disease |
X | 13 | 30 | 42 | 1 study report on the clinical status and behaviour of animals during experiments
1 study report on the dynamics of hematological and biochemical parameters of experimental animals |
|||
2.4 Sub-activity 2.4.
Set-up of the preclinical study biobank |
28 | 16 | 43 | 1 precinical study- dedicated biobank
1 biological samples registry |
||||
2.5 Sub-activity 2.5.
Set-up of the preclinical study database |
28 | 16 | 43 | 1 preclinical study database | ||||
2.6 Sub-activity 2.6.
Statistical processing of data and interpretation of results |
10 | 37 | 46 | 1 network of altered redox and inflammation processes in experimental AD models
1 report on the impact of Nrf2 activators on AD onset and progression in experimental models of disease, in connection with changes elicited by the treatment at the level of Nrf2 signature |
||||
Activity 3
Industrial research Elaboration of final study-specific Standard Operating Procedures |
3.1 Sub-activity 3.1.
Elaboration of final study-specific Standard Operating Procedures |
X | 3 | 45 | 47 | 13 Standard Operating Procedures | ||
Activity 4
Industrial research Implementation of redox biology tools at IVB |
4.1. Sub-activity 4.1.
Elaboration of training materials |
X | 4 | 5 | 8 | 5 powerpoint presentations on redox biology experimental tools
4 Standard Operating Procedures for particular redox biology experimental tools |
||
4.2. Sub-activity 4.2.
On-line training |
X | 4 | 9, 21,
33, 44 |
9, 21,
33, 44 |
4 sessions of on-line training on redox biology concepts and investigational tools | |||
4.3. Sub-activity 4.3.
On-site training |
X | 4 | 11, 23,
35, 47 |
11, 23,
35, 47 |
4 hands-on training sessions on experimental methods for investigating the redox status and the antioxidant resonse | |||
4.4 Sub-activity 4.4.
Show-and-tell workshop |
X | 1 | 47 | 47 | 1 show-and-tell workshop
3 PowerPoint presentations Promotion materials:10 posters, 50 bags with brochure, USB, pens 15 feedback questionnaires |
|||
Activity 5
Industrial research Dissemination of results |
5.1 Sub-activity 5.1. Dissemination of scientific results generated in the project | |||||||
Publication of results | X | 36 | 13 | 48 | At least 8 articles with original results out of which 3 articles will be published in collaboration with private companies
1 review article |
|||
Communication of results | X | 40 | 9 | 48 | At least 12 communications at national and international meetings out of which 4 will be published in collaboration with private companies | |||
Elaboration and submission of the documentation for patenting original results obtained in the project | X | 12 | 37 | 48 | Documentation for 1 patent/1 panel of biomarkers submitted to the Romanian Office for Inventions and Trademarks and/or similar EU patent offices | |||
Joining of new European scientific networks/platforms in the field of the project | X | 24 | 25 | 48 | Membership to at least 1 European network in the field of the project | |||
Industry showcase | X | 2 | 34 | 35 | 1 industry show case
50 invitations,3 PowerPoint presentations Promotion materials:10 posters, 1 banner, 50 bags with brochure, USB, pens Specific agreements between relevant biopharmaceutical companies and IVB for collaborative RDI work |
|||
Knowhow and technology transfer to private companies | X | 12 | 37 | 48 | 1 documentation for knowhow and technology transfer | |||
Activities of experimental development – NOT THE CASE | ||||||||
Activity of preparing the feasibility study for experimental development – NOT THE CASE | ||||||||
Activities for obtaining, validating and protecting the industrial property rights – NOT THE CASE | ||||||||
Information and publicity | ||||||||
Activity 6
Information and publicity |
6.1 Sub-activity 6.1. Information and publicity for the project | |||||||
Set-up of the project-dedicated web page | X | 48 | 1 | 48 | 1 project-dedicated web page | |||
Project’s opening and closing conferences | X | 1 | 4, 47 | 4, 47 | 2 conference programs; 100 invitations
10 posters, 2 banner1 and 1 roll-up for publicity; 80 bags containing a brochure, USB and pen, along with project promotion documents; 6 PowerPoint presentations; 50 feed-back questionnaires from participants |
|||
Publication of project promotion articles | X | 48 | 1 | 48 | 3 project promotion articles | |||
Activity 7
Project management |
7.1 Sub-activity 7.1.
General coordination and monitoring of the project |
X | 48 | 1 | 48 | 4 internal progress reports | ||
7.2 Sub-activity 7.2.
Detailed planning of work and responsibilities assignment |
X | 48 | 1 | 48 | 16 work plans | |||
7.3 Sub-activity 7.3.
Alocation and management of resources |
X | 48 | 1 | 48 | 4 detailed plans correlating activities with financial, human and material resources | |||
7.4 Sub-activity 7.4.
Procurement of material resources |
X | 48 | 1 | 48 | 8 procedures of aquisition and corresponding documentation (2 sessions per year estimated) | |||
7.5 Sub-activity 7.5.
Management meetings |
X | 48 | 1 | 48 | 8 management meetings (2 per year)
8 management meetings reports |
|||
7.6 Sub-activity 7.6.
Scientific meetings of the team |
X | 48 | 1 | 48 | 8 scientific meatings (2 per year)
8 scientific meeting reports |
|||
7.7 Sub-activity7.7.
Work group meetings |
X | 48 | 1 | 48 | 48 meetings of the implementation team ( monthly meetings)
Meeting reports |
|||
7.8 Sub-activity 7.8.
Reporting |
X | 46 | 3 | 48 | 12 intermediary reports (at three months)
1 final report |
|||
Final report | ||||||||
Activity 8
Intermediary and final audits for the project |
8.1 Sub-activity 8.1.
Preparation of the audit documentation |
X | 4 | 1 | 48 | 4 audit documentations | ||
8.2 Sub-activity 8.2.
Audits |
X | 8 | 11-12, 23-24, 35-36, 47-48 | 11-12, 23-24, 35-36, 47-48 | 4 audit certificates and reports |